Wayne Kuznar

Articles

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.

Ropeginterferon-Treated Patients With Polycythemia Vera Significantly More Likely to Be Phlebotomy Free at 5 Years

December 22nd 2020

December 22, 2020 - Patients with polycythemia vera who received ropeginterferon alfa-2b had a higher likelihood of being phlebotomy free in the fourth or fifth year of treatment vs those who received best available therapy.

Idasanutlin Induces Responses in Polycythemia Vera, but GI AEs Lead to Frequent Dose Interruptions

December 22nd 2020

December 22, 2020 - Idasanutlin, an investigational MDM2 antagonist that leads to increased p53 activity, led to hematologic responses in about two-thirds of patients with hydroxyurea-resistant polycythemia vera, but was associated with frequent discontinuation.

Early MRD Monitoring in Younger Patients With MCL Posttransplant Predicts Outcomes

December 22nd 2020

December 22, 2020 - Minimum residual disease negativity in the bone marrow and peripheral blood prior to autologous stem cell transplant predicts better progression-free survival and overall survival in younger patients with mantle cell lymphoma.

Interferon-Alpha Reduces Myelofibrosis Risk, Mortality Rate in Low- and High-Risk Polycythemia Vera

December 21st 2020

December 21, 2020 - Interferon-alpha can delay and possibly prevent post-PV myelofibrosis and improve survival in patients with polycythemia vera.

Sequential Immunotherapy May Not Be Optimal Treatment for TP53+ MCL, But Potentially TP53 Wild-Type Disease

December 18th 2020

December 18, 2020 - Sequential immunotherapy with rituximab-based therapy and the addition of lenalidomide proved effective among patients with TP53 wild-type mantle cell lymphoma, even among those with a Ki-67 level of at least 30% and/or blastoid morphology.

Liso-Cel Proves to Be Highly Active, Tolerable in Relapsed/Refractory MCL

December 17th 2020

December 17, 2020 - Lisocabtagene maraleucel exhibited promising antitumor activity with low rates of grade 3 or higher cytokine release syndrome and neurotoxicity in patients with relapsed/refractory mantle cell lymphoma.

Nivolumab/SBRT Data Leave Role of Radiation Unclear in RCC

February 17th 2020

Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma; however, the combination did not meet the primary endpoint of overall response rate.

Nivolumab Neoadjuvant Regimen Nears 50% pCR in MIBC

February 16th 2020

The neoadjuvant regimen of nivolumab combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49% in patients with muscle-invasive bladder cancer.

Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

February 15th 2020

A neoadjuvant regimen of durvalumab plus olaparib induced a pathologic complete response rate of 50% in patients with muscle-invasive bladder carcinoma.

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

February 14th 2020

Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.

Cabozantinib Shows Strength After Immunotherapy in Renal Cell Carcinoma

February 10th 2020

Cabozantinib demonstrated impressive progression free survival when administered post-immunotherapy in patients with metastatic renal cell carcinoma.

QoL Superior With Atezolizumab/Bevacizumab Versus Sorafenib in Frontline HCC

January 28th 2020

Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.

Triplet and Doublet Regimens Outperform Standard of Care on Survival, QoL in BRAF+ CRC

January 27th 2020

Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.

Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC

January 27th 2020

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

Second-Line Ramucirumab Improves OS in AFP-Elevated HCC, Regardless of Disease Stage

January 27th 2020

Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.

High Responses Observed With Avelumab Added to Regimen for Metastatic Colorectal Cancer Does Not Translate to PFS

January 26th 2020

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer

January 25th 2020

The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation.

Frontline Lenvatinib with Subsequent Therapy Improves Survival in Unresectable HCC

January 25th 2020

Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.

Addition of Cabozantinib to Ipi/Nivo Shows Promising Antitumor Activity in Advanced HCC

January 25th 2020

The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.